Samaritan Pharmaceuticals, Inc.'s Last-Ditch Salvage Therapy SP-01A Fighting “HIV Drug Resistance,” Issued US Patent

LAS VEGAS--(BUSINESS WIRE)--Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company, committed to commercializing new innovative therapeutic drugs, announces its proprietary HIV drug, SP-01A, is awarded US patent No: US 7,354,906 B2, entitled “Composition of Anti-HIV drugs and Anti-Cortisol compounds and Methods for Decreasing the Side Effects of Anti-HIV drugs in Humans” by the Director of the United States Patent and Trademark Office.

MORE ON THIS TOPIC